Read more about Intas Pharma files draft prospectus for IPO on Business Standard. Drug maker Intas Pharmaceuticals today said it has filed. Intas Pharmaceuticals, has filed its draft red herring prospectus (DRHP) with Securities and Exchange Board of India (SEBI) for an initial public. Intas Pharma DRHP News: Latest and Breaking News on Intas Pharma DRHP. Explore Intas Pharma DRHP profile at Times of India for photos, videos and latest .
|Published (Last):||14 September 2013|
|PDF File Size:||20.31 Mb|
|ePub File Size:||18.62 Mb|
|Price:||Free* [*Free Regsitration Required]|
Intas Pharma merges group companies, subsidiaries. All rights reserved Disclaimer.
Intas Pharma files draft prospectus for IPO | Business Standard News
Intas to buy Teva’s UK, Ireland assets for mn pounds. Intas Pharma files for an IPO. The promoters of inta company are Mr. The IPO will be made through a public issue of equity shares of face value of Rs.
Drugs sold sans regulator’s nod, safety studies. According to sources, the company has begun the groundwork for the IPO and approached merchant bankers a couple of months ago. Monday, 31 December dhp Please click here to Sign-in or Sign-up. Visit Our Digital Magazine: New Delhi, May 26 RPG Life Sciences has sold its Gujarat-based biotechnology unit to Intas Pharmaceuticals for Rs 25 crore to focus on core areas of business and improve long-term competitiveness in a rapidly changing market.
Sun Pharma in early talks to buy Intas Pharma. Intas Pharma buys Spanish company’s hospital business. Mon, Dec 31, Updated Drug-maker Intas Pharmaceuticals has merged all its group companies and subsidiaries over concerns about low profits.
Intas Pharma files draft prospectus for IPO
Web Interface Conceived and Powered By: Rahul Gandhi listed as ‘non-Hindu’. Desi pharma companies top in biosimilars globally. Intas Pharma eyes hospitals in Europe, US. Hyderabad-based pharma giant Aurobindo snaps up Portuguese co for Rs crore. It has also extended its presence into other therapy areas such as gynecology, infertility, arthritis and the respiratory.
Intas Pharmaceuticals files DRHP for IPO
We will get in touch with you shortly. From around the Web. Enquiry Thanks for contacting us! Its products are marketed in over 60 countries, either directly, through its subsidiaries or indirectly, through supply, distribution and other arrangements with various leading global pharmaceutical companies.
Intas Pharma launches first etanercept biosimilar.
Medical Council of India MCI will investigate a complaint against 11 doctors from Madhya Pradesh who are charged with accepting foreign jaunts sponsored by pharmaceutical company.
It is currently ranked as the 12th largest pharmaceutical company in the country with a 2. Subscribe to BioSpectrum India.
Nimish Hasmukhbhai Chudgar, Dr. Email Enter a valid email address. In what could further strengthen its business in European and non-European countries, Ahmedabad based Intas Pharmaceuticals Ltd has acquired hospital business of Combino Pharm in Spain and Portugal for an undisclosed sum.
Intas Pharma is a vertically integrated Indian pharmaceutical company with global operations, engaged in the development, manufacture and marketing of pharmaceutical formulation. At present, domestic companies are marketing their products only in emerging markets, but the largest and most lucrative market for all pharmaceuticals — the US — is the next stop.
Sources said the group has started a process to sell drug discovery services company Advinus Therapeutics, drawing interest from private equity funds Kedaara Capital and True North as well as from strategic players, GVK Biosciences and Lambda, a unit of Intas Pharma. The company is present in various major therapy areas such as those relating to neurology, psychiatry, cardiology, pain management, gastroenterology, diabetology, nephrology, urology, anti-infective therapy, dermatology, gynecology, respiratory system, oncology, critical care and ophthalmology with a strong focus on chronic therapy areas relating to neurology, psychiatry, cardiology and diabetology.
ChrysCap backs Curatio in latest pharma bet. MCI to probe foreign jaunts by MP doctors.
Binish Hasmukh Chudgar, Mr. Please fill the all fields. The Ahmedabad-based company is considering licensing agreements with hospital-based businesses in these markets. Please note that comments are moderated and are generally published if they are on-topic and not abusive.
Chandra kicks off divestment plan.